BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors: CYP2C19 AND PROTON PUMP INHIBITORS. Basic & Clinical Pharmacology & Toxicology 2004;95:2-8. [DOI: 10.1111/j.1600-0773.2004.pto950102.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008;64:1181-8. [DOI: 10.1007/s00228-008-0533-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
2 Ginya H, Matsushita R, Yohda M. Quantification and improvement of error rate during ligase detection reaction. Journal of Bioscience and Bioengineering 2010;109:202-4. [DOI: 10.1016/j.jbiosc.2009.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Koch KM, Im YH, Kim SB, Urruticoechea Ribate A, Stephenson J, Botbyl J, Cartee L, Holshouser J, Ridgway D. Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. Clin Pharmacol Drug Dev 2013;2:336-41. [PMID: 27121938 DOI: 10.1002/cpdd.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
4 Koyanagi T, Nakanishi Y, Murayama N, Yamaura Y, Ikeda K, Yano K, Uehara S, Utoh M, Kim S, Uno Y, Yamazaki H. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R -/ S -warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro–in vivo correlation. Xenobiotica 2014;45:312-21. [DOI: 10.3109/00498254.2014.979271] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
5 Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76. [PMID: 19514965 DOI: 10.1080/03602530902722679] [Cited by in Crossref: 414] [Cited by in F6Publishing: 321] [Article Influence: 31.8] [Reference Citation Analysis]
6 Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochemical Pharmacology 2011;81:1145-51. [DOI: 10.1016/j.bcp.2011.02.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 6.3] [Reference Citation Analysis]
7 Fernando H, Dart AM, Peter K, Shaw JA. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost. 2011;105:933-944. [PMID: 21544314 DOI: 10.1160/th10-11-0715] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
9 Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. Am J Gastroenterol. 2006;101:1467-1475. [PMID: 16863547 DOI: 10.1111/j.1572-0241.2006.00717.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 6.6] [Reference Citation Analysis]
10 Pu J, Wang F, Tang W, Zhu M. Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction. Drug Metab Dispos 2018;46:1453-61. [PMID: 30002078 DOI: 10.1124/dmd.118.081570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Review of Anti-infective Therapy 2014;3:863-70. [DOI: 10.1586/14787210.3.6.863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
12 Singh H, Mittal BR, Sood A, Bollampally N, Gorla AKR, Dasagrandhi V, Parmar M. Association of use of proton pump inhibitors and H2 antagonists with stomach wall uptake in 99mTc-methoxy-isobutyl-isonitrile (MIBI) myocardial perfusion imaging. J Nucl Cardiol 2020;27:1611-9. [DOI: 10.1007/s12350-019-01733-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
13 Piñol C. Evaluación económica del tratamiento con ácido acetilsalicílico más esomeprazol comparado con clopidogrel en la prevención de la hemorragia gastrointestinal. Gaceta Sanitaria 2006;20:54-7. [DOI: 10.1157/13084128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
15 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31. [PMID: 18925391 DOI: 10.1007/s00228-008-0576-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 8.9] [Reference Citation Analysis]
16 Lin YS, Thummel KE, Thompson BD, Totah RA, Cho CW. Sources of Interindividual Variability. Methods Mol Biol 2021;2342:481-550. [PMID: 34272705 DOI: 10.1007/978-1-0716-1554-6_17] [Reference Citation Analysis]
17 Niioka T, Uno T, Yasui-Furukori N, Shimizu M, Sugawara K, Tateishi T. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Eur J Clin Pharmacol 2006;62:855-61. [PMID: 16915367 DOI: 10.1007/s00228-006-0184-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Harvey A, Modak A, Déry U, Roy M, Rinfret S, Bertrand OF, Larose É, Rodés-cabau J, Barbeau G, Gleeton O, Nguyen CM, Proulx G, Noël B, Roy L, Paradis J, De Larochellière R, Déry J. Changes in CYP2C19 enzyme activity evaluated by the [ 13 C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J Breath Res 2016;10:017104. [DOI: 10.1088/1752-7155/10/1/017104] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
19 Nagase M, Shimada H, Nii M, Ueda S, Higashimori M, Ichikawa K, Zhang L, Zhou L, Chen Y, Zhou D, Dunyak J, Al-Huniti N. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. J Clin Pharm Ther 2020;45:1030-8. [PMID: 32227647 DOI: 10.1111/jcpt.13129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, Agarwala S, Dragone J, Bertz R. Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects. The Journal of Clinical Pharmacology 2011;51:368-77. [DOI: 10.1177/0091270010367651] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
21 Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton Pump Inhibitors Accelerate Endothelial Senescence. Circ Res 2016;118:e36-42. [PMID: 27166251 DOI: 10.1161/CIRCRESAHA.116.308807] [Cited by in Crossref: 63] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
22 Saito YA, Camilleri M. Clinical application of pharmacogenetics in gastrointestinal diseases. Expert Opin Pharmacother 2006;7:1857-69. [PMID: 17020413 DOI: 10.1517/14656566.7.14.1857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
23 Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, Hsu PI, Chen A, Hung WC, Yang YC. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15:265-272. [PMID: 20633187 DOI: 10.1111/j.1523-5378.2010.00761.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
24 Stingl JC, Just KS, Kaumanns K, Schurig-Urbaniak M, Scholl C, von Mallek D, Brockmöller J. [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice]. Internist (Berl) 2016;57:289-97. [PMID: 26830424 DOI: 10.1007/s00108-015-0013-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Kerb R, Fux R, Mörike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. The Lancet Infectious Diseases 2009;9:760-74. [DOI: 10.1016/s1473-3099(09)70320-2] [Cited by in Crossref: 93] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
26 Jha A, Kumar A. Development and targeting of transcriptional regulatory network controlling FLU1 activation in Candida albicans for novel antifungals. Journal of Molecular Graphics and Modelling 2016;69:1-7. [DOI: 10.1016/j.jmgm.2016.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
27 Reyes D, Ortiz J, Fuentes-López E, Budnik S, Gandara V, Gallardo A, Seydewitz MF, Candia R, Ignacio Vargas J, Rollan MP, Godoy J, Rollan A, Mansilla R, Arenas A, Chahuán J, Espino A, Pizarro M, Riquelme A. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterol Hepatol 2021:S0210-5705(21)00320-4. [PMID: 34890721 DOI: 10.1016/j.gastrohep.2021.11.010] [Reference Citation Analysis]
28 Modak AS, Klyarytska I, Kriviy V, Tsapyak T, Rabotyagova Y. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole- 13 C breath test in GERD patients: clinical relevance for personalized medicine. J Breath Res 2016;10:046017. [DOI: 10.1088/1752-7163/10/4/046017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
29 Janha RE, Sisay-Joof F, Hamid-Adiamoh M, Worwui A, Chapman HL, Opara H, Dunyo S, Milligan P, Rockett K, Winstanley P, Pirmohamed M, Miller AK, Conway DJ, Walton RT. Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics 2009;10:1423-31. [PMID: 19761366 DOI: 10.2217/pgs.09.72] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
30 Blümel B, Goelz H, Kist M, Glocker E. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 2018;23:e12494. [DOI: 10.1111/hel.12494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
31 Sheng YC, Wang K, He YC, Yang J, Zheng QS. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2010;66:1165-9. [PMID: 20838991 DOI: 10.1007/s00228-010-0892-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
32 Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci 2005;360:1617-38. [PMID: 16096112 DOI: 10.1098/rstb.2005.1693] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
33 Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R. Where Failure Is Not an Option -Personalized Medicine in Astronauts. PLoS One 2015;10:e0140764. [PMID: 26489089 DOI: 10.1371/journal.pone.0140764] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
34 Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 2009;10:43-9. [DOI: 10.2217/14622416.10.1.43] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
35 Treiber G, Malfertheiner P, Klotz U. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007;8:329-50. [PMID: 17266468 DOI: 10.1517/14656566.8.3.329] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
36 Udelnow A, Kreyes A, Ellinger S, Landfester K, Walther P, Klapperstueck T, Wohlrab J, Henne-Bruns D, Knippschild U, Würl P. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One 2011;6:e20143. [PMID: 21629657 DOI: 10.1371/journal.pone.0020143] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
37 Vormfelde SV, Schirmer M, Toliat MR, Meineke I, Kirchheiner J, Nürnberg P, Brockmöller J. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenomics J 2007;7:200-11. [DOI: 10.1038/sj.tpj.6500410] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
38 Kirchheiner J, Schwab M. HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. Pharmacology and Therapeutics. Elsevier; 2009. pp. 225-38. [DOI: 10.1016/b978-1-4160-3291-5.50020-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Seo KA, Lee SJ, Kim KB, Bae SK, Liu KH, Kim DH, Shin JG. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42:278-284. [PMID: 22022918 DOI: 10.3109/00498254.2011.622416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
40 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103-141. [PMID: 23333322 DOI: 10.1016/j.pharmthera.2012.12.007] [Cited by in Crossref: 1787] [Cited by in F6Publishing: 1543] [Article Influence: 198.6] [Reference Citation Analysis]
41 Wynn GH, Sandson NB, Cozza KL. Gastrointestinal medications. Psychosomatics 2007;48:79-85. [PMID: 17209156 DOI: 10.1176/appi.psy.48.1.79] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008;65:767-74. [PMID: 18294333 DOI: 10.1111/j.1365-2125.2008.03104.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 7.3] [Reference Citation Analysis]
43 Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007;8:2701-2717. [PMID: 17956193 DOI: 10.1517/14656566.8.16.2701] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
44 Venkataraman R, Rashid M, Shrestha H. Inappropriate Medication Use and Cost Comparison Analysis of Proton Pump Inhibitors: Evidence from an Indian Tertiary Care Facility. Curr Drug Saf 2020;15:147-55. [PMID: 32160850 DOI: 10.2174/1574886315666200311120151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
45 Díaz-Ordóñez L, Ramírez-Montaño D, Candelo E, González-Restrepo C, Silva-Peña S, Rojas CA, Sepulveda Copete M, Echavarria HR, Pachajoa H. Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole. Pharmgenomics Pers Med 2021;14:509-20. [PMID: 33953602 DOI: 10.2147/PGPM.S285144] [Reference Citation Analysis]
46 Draeger S, Wüppenhorst N, Kist M, Glocker EO. Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing. J Antimicrob Chemother 2015;70:3141-5. [PMID: 26245638 DOI: 10.1093/jac/dkv223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Guo Y, Shafer S, Weller P, Usuka J, Peltz G. Pharmacogenomics and drug development. Pharmacogenomics 2005;6:857-64. [PMID: 16296948 DOI: 10.2217/14622416.6.8.857] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
48 Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem. Helicobacter. 2016;21:349-363. [PMID: 26822340 DOI: 10.1111/hel.12299] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
49 Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother. 2009;63:648-653. [PMID: 19190100 DOI: 10.1093/jac/dkp003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
50 Bramness JG, Skurtveit S, Gulliksen M, Breilid H, Steen VM, Mørland J. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. Eur J Clin Pharmacol 2005;61:499-506. [PMID: 16021435 DOI: 10.1007/s00228-005-0970-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
51 Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20(43): 16029-16036 [PMID: 25473155 DOI: 10.3748/wjg.v20.i43.16029] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
52 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
53 Cojutti P, Candoni A, Forghieri F, Isola M, Zannier ME, Bigliardi S, Luppi M, Fanin R, Pea F. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. Basic Clin Pharmacol Toxicol 2016;118:474-9. [PMID: 26572687 DOI: 10.1111/bcpt.12530] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
54 Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta. 2008;391:60-67. [PMID: 18319058 DOI: 10.1016/j.cca.2008.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
55 Shao H, Ren XM, Liu NF, Chen GM, Li WL, Zhai ZH, Wang DW. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther 2010;35:351-60. [PMID: 20831536 DOI: 10.1111/j.1365-2710.2009.01134.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
56 Smith G, Davis J, Smith S, Gerard M, Campbell N, Foster D. Efficacy and Pharmacokinetics of Pantoprazole in Alpacas: Pantoprazole in Alpacas. Journal of Veterinary Internal Medicine 2010;24:949-55. [DOI: 10.1111/j.1939-1676.2010.0508.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
57 Hofmann U, Schwab M, Treiber G, Klotz U. Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography–mass spectrometry. Journal of Chromatography B 2006;831:85-90. [DOI: 10.1016/j.jchromb.2005.11.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
58 Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008;65:437-439. [PMID: 18241287 DOI: 10.1111/j.1365-2125.2007.03057.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.4] [Reference Citation Analysis]
59 Kuzin M, Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clin Pharmacokinet 2018;57:729-37. [PMID: 28866861 DOI: 10.1007/s40262-017-0591-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
60 Shao F, Sun J, Wang G, Xie H, Zhu X, Zhang J. Liquid chromatographic–mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. Biopharm Drug Dispos 2007;28:177-86. [DOI: 10.1002/bdd.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
61 Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251-9. [DOI: 10.2217/14622416.9.9.1251] [Cited by in Crossref: 161] [Cited by in F6Publishing: 138] [Article Influence: 11.5] [Reference Citation Analysis]
62 Camilleri M, Saito YA. Pharmacogenomics in Gastrointestinal Disorders. In: Yan Q, editor. Pharmacogenomics in Drug Discovery and Development. Totowa: Humana Press; 2008. pp. 395-412. [DOI: 10.1007/978-1-59745-205-2_13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
63 Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49-59. [PMID: 22649281 DOI: 10.2147/ceg.s23926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
64 Klotz U, Treiber G, Schwab M. Determinants of non-response in Helicobacter pylori eradication trials. J Gastroenterol Hepatol 2005;20:1471. [PMID: 16105147 DOI: 10.1111/j.1440-1746.2005.03846.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
66 Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35. [PMID: 23350044 DOI: 10.5056/jnm.2013.19.1.25] [Cited by in Crossref: 177] [Cited by in F6Publishing: 153] [Article Influence: 19.7] [Reference Citation Analysis]
67 Kopic S, Geibel JP. Gastric acid, calcium absorption, and their impact on bone health. Physiol Rev 2013;93:189-268. [PMID: 23303909 DOI: 10.1152/physrev.00015.2012] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
68 Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010;6:29-41. [PMID: 19968574 DOI: 10.1517/17425250903386251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
69 Funck-brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V, Azizi M, Gaussem P. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Archives of Cardiovascular Diseases 2013;106:661-71. [DOI: 10.1016/j.acvd.2013.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
70 Camilleri M. The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2012;9:173-184. [PMID: 22310916 DOI: 10.1038/nrgastro.2012.2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
71 Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly. Drugs Aging 2014;31:263-82. [DOI: 10.1007/s40266-014-0166-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
72 Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol 2018;11:119-34. [PMID: 29606884 DOI: 10.2147/CEG.S121056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
73 Zuern CS, Schwab M, Gawaz M, Geisler T. Platelet pharmacogenomics. J Thromb Haemost 2010;8:1147-58. [PMID: 20128862 DOI: 10.1111/j.1538-7836.2010.03791.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
74 Xuan JW, Song RL, Xu GX, Lu WQ, Lu YJ, Liu Z. Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China. J Med Econ 2016;19:1056-60. [PMID: 27223846 DOI: 10.1080/13696998.2016.1194277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
75 Liu MK, Wu IC, Lu CY, Kuo CH, Yu FJ, Liu CJ, Hsu PI, Hsu WH, Su YC, Chen A. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens. Kaohsiung J Med Sci. 2013;29:379-384. [PMID: 23768702 DOI: 10.1016/j.kjms.2012.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
76 Clarke W, McMillin G. Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs. Per Med 2006;3:139-49. [PMID: 29793289 DOI: 10.2217/17410541.3.2.139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 2008;8:4-15. [PMID: 17549068 DOI: 10.1038/sj.tpj.6500462] [Cited by in Crossref: 82] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
78 Yang JC, Yang YF, Uang YS, Lin CJ, Wang TH. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol. 2009;67:503-510. [PMID: 19552744 DOI: 10.1111/j.1365-2125.2009.03393.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
79 Alonso-navarro H, Jiménez-jiménez FJ, García-agúndez JA. Papel del polimorfismo genético CYP2C19 en los efectos adversos a fármacos y en el riesgo para diversas enfermedades. Medicina Clínica 2006;126:697-706. [DOI: 10.1157/13088772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Jonaitis P, Jonaitis L, Kupcinskas J. Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication Regimens. Curr Drug Metab. 2020;. [PMID: 32407266 DOI: 10.2174/1389200221666200514081442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 de Bortoli N, Martinucci I, Giacchino M, Blandizzi C, Marchi S, Savarino V, Savarino E. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opin Drug Metab Toxicol. 2013;9:1361-1369. [PMID: 23802731 DOI: 10.1517/17425255.2013.813018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
82 Lee Y, Lin J, Wang H, Chiu H, Wu M. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol 2007;22:1286-92. [DOI: 10.1111/j.1440-1746.2007.04942.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
83 Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. Int J Mol Sci 2019;20:E5203. [PMID: 31640115 DOI: 10.3390/ijms20205203] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
84 Mwinyi J, Hofmann Y, Pedersen RS, Nekvindová J, Cavaco I, Mkrtchian S, Ingelman-sundberg M. The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sciences 2010;86:699-706. [DOI: 10.1016/j.lfs.2010.02.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
85 Ji HY, Lee HW, Kim H, Choi J, Lee HS. Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H+/K+-ATPase inhibitor KR-60436. Toxicology Letters 2005;155:103-14. [DOI: 10.1016/j.toxlet.2004.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
86 Miyamoto S, Tsuda M, Kato M, Mabe K, Muto S, Ono S, Shimizu Y, Sakamoto N. Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test. J Clin Biochem Nutr 2019;64:174-9. [DOI: 10.3164/jcbn.18-75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Di Mario F, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113-130. [PMID: 16699270 DOI: 10.1159/000090315] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
88 Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy 2013;33:956-71. [PMID: 23712734 DOI: 10.1002/phar.1299] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
89 Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005;22:10-9. [DOI: 10.1111/j.1365-2036.2005.02715.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
90 Saito YA, Talley NJ. AJG series: molecular biology for clinicians. Am J Gastroenterol 2009;104:2583-7. [PMID: 19550416 DOI: 10.1038/ajg.2009.319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
91 Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother 2006;40:639-44. [PMID: 16595569 DOI: 10.1345/aph.1G464] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
92 Matsukawa J, Kogame A, Tagawa Y, Inatomi N. Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa. Dig Dis Sci 2016;61:1888-94. [PMID: 26961787 DOI: 10.1007/s10620-016-4100-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
93 Jenkins H, Jenkins R, Patat A. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. Clin Drug Investig 2017;37:311-6. [PMID: 27928738 DOI: 10.1007/s40261-016-0488-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
94 Hojo M, Asaoka D, Takeda T, Shimada Y, Matsumoto K, Matsumoto K, Yatagai N, Akazawa Y, Ueda K, Ueyama H, Nagahara A. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol 2020;13:1756284820966247. [PMID: 33240391 DOI: 10.1177/1756284820966247] [Reference Citation Analysis]
95 Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H, Saito T, Nakamura T, Yamao K, Hamajima N, Tajima K. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect 2007;135:171-6. [PMID: 16740190 DOI: 10.1017/S0950268806006613] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
96 Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008;84:347-61. [PMID: 18231117 DOI: 10.1038/sj.clpt.6100482] [Cited by in Crossref: 160] [Cited by in F6Publishing: 132] [Article Influence: 11.4] [Reference Citation Analysis]
97 Wang Y, Zhang H, Meng L, Wang M, Yuan H, Ou N, Zhang H, Li Z, Shi R. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010;66:563-9. [PMID: 20414645 DOI: 10.1007/s00228-010-0821-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
98 Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S. Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol 2016;81:1078-90. [PMID: 26774055 DOI: 10.1111/bcp.12884] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
99 Savarino E, Martinucci I, Furnari M, Romana C, Pellegatta G, Moscatelli A, Bodini G, Marabotto E, Savarino V, de Bortoli N, Blandizzi C. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1333-41. [DOI: 10.1080/17425255.2016.1214714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
100 van Zanten SV, Thompson K. Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? Am J Gastroenterol 2006;101:1476-8. [PMID: 16863548 DOI: 10.1111/j.1572-0241.2006.00714.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
101 Tran-Duy A, Connell NJ, Vanmolkot FH, Souverein PC, de Wit NJ, Stehouwer CDA, Hoes AW, de Vries F, de Boer A. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med 2019;285:205-14. [PMID: 30141278 DOI: 10.1111/joim.12826] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
102 Klotz U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol 2009;65:1-2. [DOI: 10.1007/s00228-008-0571-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
103 Gómez-Torrijos E, García-Rodríguez R, Castro-Jiménez A, Rodríguez-Sanchez J, Méndez Díaz Y, Molina-Infante J. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther 2016;43:534-40. [PMID: 26662868 DOI: 10.1111/apt.13496] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
104 Tseng P, Lee Y, Chiu H, Wang H, Lin J, Wu M. A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes. Journal of Clinical Gastroenterology 2009;43:920-5. [DOI: 10.1097/mcg.0b013e3181960628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
105 Savarino E, Ottonello A, Martinucci I, Dulbecco P, Savarino V. Ilaprazole for the treatment of gastro-esophageal reflux. Expert Opinion on Pharmacotherapy 2016;17:2107-13. [DOI: 10.1080/14656566.2016.1232389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
106 Kitay AM, Geibel JP. Stomach and Bone. In: Mccabe LR, Parameswaran N, editors. Understanding the Gut-Bone Signaling Axis. Cham: Springer International Publishing; 2017. pp. 97-131. [DOI: 10.1007/978-3-319-66653-2_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]